MACULAR PHOTOCOAGULATION STUDY

黄斑光凝研究

• 批准号: 3559181
• 负责人: GARY FISH
• 金额: $ 3.65万
• 依托单位: TEXAS RETINA ASSOCIATES, INC.
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-09-30 至 1993-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3559181
• 关键词: aging; disease /disorder prevention /control; eye laser surgery; eye surgery; human subject; human therapy evaluation; patient /disease registry; photocoagulation therapy; retina degeneration; vision tests

The proposed Foveal Photocoagulation Study is a multicenter study of treatment for age-related macular degeneration (AMD) in eyes with subfoveal neovascular lesions. The study consists of two randomized controlled trials of laser photocoagulation treatment and a natural history study of eyes ineligible for the trials. Eligible AMD patients who meet the visual acuity criteria for the randomized trials (20/80 vA 20/320) will be assigned to treatment or to no treatment of the neovascular lesion. Nature history study patients will have AMD and a subfoveal neovascular lesion but visual acuity better than 20/80. The purpose of the randomized trials is to determine whether krypton red laser photocoagulation is effective in preventing or delaying severe loss of vision in AMD patients who have subfoveal lesions, whether there are new neovascular lesions or recurrent neovascularization subfoveally following prior treatment for extrafoveal or juxtafoveal lesions. The purpose of the natural history study is to determine the rate at which visual acuity deteriorate to 20/80 or worse in eyes with AMD and subfoveal neovascular membranes after initial clinical presentation of patients who would otherwise be eligible for the randomized trials. The study will be carried out in twelve Clinical Centers, a Coordinating Center, and a Fundus Photograph Reading Center; the study investigators and centers consist primarily of those who have collaborated in the Macular Photocoagulation Study (MPS) over the past six years.

建议的中心凹光凝研究是一项多中心的研究 黄斑中心凹下老年性黄斑变性的治疗 新生血管损伤。该研究由两组随机对照组成 激光光凝治疗的试验和自然病史研究 眼睛没有资格参加选拔赛。符合视力的符合条件的AMD患者 随机试验(20/80Va 20/320)的视力标准为 被分配到新生血管病变的治疗或不治疗。自然界 病史研究患者将患有AMD和中心凹下新生血管病变，但 视力优于20/80。 随机试验的目的是确定氪红是否 激光光凝可有效预防或延缓严重的失血。 黄斑中心凹下损害的AMD患者的视力，是否有新的 中心凹下新生血管病变或复发性新生血管 黄斑外或黄斑旁病变的优先治疗。该计划的目的是 自然史研究是为了确定视力 患有AMD和中心凹下新生血管的眼睛恶化到20/80或更差 患者首次临床表现后的胎膜 否则有资格参加随机试验。 这项研究将在12个临床中心进行，协调 中心和眼底照片阅读中心；研究调查人员和 中心主要由那些在Macular中合作的人组成 过去六年的光凝研究(MPS)。